Cycle Pharmaceuticals launces Sajazir (icatibant) Injection, a new treatment option for patients affected by HAE approved by the US Food and Drug Administration (FDA). Sajazir is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of HAE in adults 18 years of age and older.

Sajazir is supplied in a prefilled syringe delivering 30 mg icatibant. Patients may self-administer Sajazir subcutaneously upon recognition of symptoms of a HAE attack after training under the guidance of a Healthcare Professional or a Registered Nurse from Cycle Vita.

“The launch of Sajazir gives the HAE community an exciting new treatment option. Cycle understands the importance of providing product support to complement the impact of therapeutic products. Sajazir patients can take advantage of our newly launched product support hub, Cycle Vita.” says Zac Bohlen, Cycle’s VP of US Sales.(Source: Cycle Pharmaceuticals)